Wolfgang M Brueckl

8PUBLICATIONS
12CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsCancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 25, 2026
Clinical management and outcomes of relapsed NSCLC after chemoradiotherapy and durvalumab consolidation: real-world evidence from Germany.

|Oct 27, 2023
Fluctuation of Acquired Resistance Mutations and Re-Challenge with EGFR TKI in Metastatic NSCLC: A Case Report.

Markus Falk, Stefanie Schatz, Fabian P M Reich

|Feb 24, 2023
Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy.

Markus Falk, Eva Willing, Stefanie Schmidt

|Mar 31, 2022
Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP).

Martin Faehling, Hanno Witte, Martin Sebastian

|May 17, 2021
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice.

Wolfgang M Brückl, Martin Reck, Frank Griesinger

|Dec 04, 2020
Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC).

Wolfgang M Brueckl, Joachim H Ficker, Gloria Zeitler

Pageof 2

Frequent Collaborators

3 joint publications

Joachim H Ficker

2 joint publications

Martin Faehling

2 joint publications

Stefanie Schatz

2 joint publications

Markus Falk